智通财经APP讯，海翔药业(002099.SZ)发布公告，公司近日收到旗下产业基金管理人北京国信中数投资 管理有限公司出具的《通知函》。公司获悉北京国信海翔股权投资合伙企业(有限合伙)(以下简称"国信 海翔")参投公司诺未生物技术(无锡)有限公司(以下简称"诺未生物")自主研发的全球首款肝癌术后预防复 发核酸新药NWRD06的Ⅱ期临床试验在中国医学科学院肿瘤医院正式启动，并已完成首例受试者入组 及首次给药。 NWRD06注射液的Ⅰ期注册临床研究已于中国医学科学院肿瘤医院完成，基于GPC3靶点的治疗策略， 其核心价值在于精准识别肿瘤细胞及手术治疗不可及的微小病灶，可以在不损伤正常组织的前提下，发 挥抗肿瘤作用。随着Ⅱ期临床试验的顺利启动和首例受试者入组，NWRD06注射液向临床应用迈出了 坚实一步，未来有望为肝癌术后患者提供安全、无创的防复发选择，提高患者的生存期，传递新的健康 希望。 NWRD06注射液是目前全球首个针对肝癌特异性靶点GPC3并进入Ⅱ期临床阶段的治疗性核酸药物，其 通过激活特异性T细胞免疫清除肿瘤细胞的机制具有创新性。基于该机制，理论上其适应症可拓展至癌 症的早期治疗阶段，即在获批肝癌术后复发 ...

Core Insights - The pharmaceutical industry is experiencing significant performance divergence among major multinational companies in 2025, with some companies thriving while others face substantial challenges [1][2][3][4]. Financial Performance - Novo Nordisk reported Q3 2025 revenues of 74.976 billion Danish Krone (approximately $11.276 billion), a year-on-year increase of 11%, with total revenues for the first three quarters reaching 229.92 billion Danish Krone (approximately $34.58 billion), up 15% [1]. - Key products such as Ozempic, Rybelsus, and Wegovy contributed significantly to Novo Nordisk's revenue, with Wegovy showing a remarkable growth of 54% [1]. - Merck's pharmaceutical revenue for the first three quarters of 2025 was $43.299 billion, with a 68% decline in revenue from China, dropping to $1.452 billion [2]. - Eli Lilly achieved a remarkable turnaround with Q3 revenues of $17.6 billion, a 54% increase year-on-year, driven by the success of its GLP-1 drug [3]. - Pfizer was the only company in the top 10 to experience a decline in both revenue and profit, with Q3 revenues of $16.654 billion, down 6% year-on-year [4]. Strategic Adjustments - Major pharmaceutical companies are actively seeking solutions to address strategic challenges, including layoffs and business divestitures, with 190 layoffs reported in the first three quarters of 2025 [2][9]. - Companies like Merck and Novo Nordisk are implementing significant cost-cutting measures, with Merck aiming to save $3 billion by 2027 and Novo Nordisk planning to cut approximately 9,000 jobs [2][9]. - The trend of divesting mature assets is becoming common, with companies opting to sell off non-core or underperforming business units to focus on innovation [7][9]. Market Dynamics - The Chinese market is no longer a guaranteed success for multinational pharmaceutical companies, with significant performance disparities emerging [5][12]. - The ongoing "patent cliff" is a critical concern, with many companies facing over 20% of their revenue at risk due to expiring patents [5]. - The competitive landscape is shifting, with local investment firms increasingly acquiring mature products from multinational companies, allowing for more localized management and decision-making [8][9]. Future Outlook - The future of multinational pharmaceutical companies will depend on their ability to innovate rapidly, adapt to local market policies, and manage patent expirations effectively [12][14]. - Companies that can successfully transition to innovation-driven models and integrate into China's biopharmaceutical ecosystem are likely to thrive [12][14]. - The restructuring of global pharmaceutical companies is creating both challenges and opportunities for local firms, as they may benefit from the divestiture of mature products and increased collaboration on early-stage innovations [14].

Core Insights - The pharmaceutical industry is experiencing significant performance divergence among major multinational companies in 2025, with some achieving remarkable growth while others face substantial declines [1][4][6]. Financial Performance - Novo Nordisk reported Q3 2025 revenues of 74.976 billion Danish Krone (approximately $11.276 billion), a year-on-year increase of 11%, with total revenues for the first three quarters reaching 229.92 billion Danish Krone (approximately $34.58 billion), up 15% [1]. - Merck's pharmaceutical business revenue for the first three quarters of 2025 was $43.299 billion, with a 68% year-on-year decline in revenue from China, dropping to $1.452 billion [2]. - Eli Lilly achieved a Q3 2025 revenue of $17.6 billion, a 54% increase from $11.439 billion in the same period last year, with total revenues for the first three quarters reaching $45.887 billion, up 46% [3]. - Pfizer's Q3 2025 total revenue was $16.654 billion, a 6% decrease from $17.702 billion year-on-year, with a 55% drop in revenue from its COVID-19 oral drug Paxlovid [4]. Strategic Adjustments - Major pharmaceutical companies are actively seeking solutions to address strategic challenges, including layoffs and business divestitures, with 190 layoffs reported in the biopharmaceutical sector in the first three quarters of 2025 [2][9]. - Companies like Merck and Novo Nordisk are implementing significant cost-cutting measures, with Merck aiming to save $3 billion by 2027 and Novo Nordisk targeting an annual cost saving of 8 billion Danish Krone [9]. - The trend of divesting mature assets is becoming common, with investment firms stepping in as buyers, indicating a shift in the operational landscape of the pharmaceutical industry in China [7][8]. Market Dynamics - The Chinese market is no longer a guaranteed profit zone for multinational pharmaceutical companies, with significant performance disparities emerging among leading firms [5][12]. - The ongoing "patent cliff" is a critical concern, with many companies facing over 20% revenue exposure to patent expirations in the next three years, impacting their financial stability [4][5]. - The competition in the pharmaceutical sector is intensifying, necessitating companies to adapt quickly to local market policies and innovate their product pipelines to maintain growth [6][12]. Future Outlook - The future of multinational pharmaceutical companies will heavily rely on their innovation capabilities, local market strategies, and management of patent expirations [12][15]. - Companies that successfully transition to innovation-driven models and establish strong positions in emerging therapeutic areas are likely to thrive, while those unable to adapt may face ongoing growth pressures [12][15]. - The restructuring of global pharmaceutical strategies is expected to accelerate, focusing on both downsizing and investing in innovative fields, such as gene and cell therapies [9][10].

来源：新浪证券-红岸工作室 12月29日，华人健康跌3.24%，成交额6.03亿元，换手率21.61%，总市值75.28亿元。 医药电商+流感+养老概念+阿里巴巴概念+创新药 异动分析 1、据2023年2月17日互动易回复：公司除阿里旗下的天猫/饿了么平台外，公司在京东/拼多多/美团等国 内主要电商平台也都有布局，并且报告期内取得了长足发展。 2、2023年11月28日互动易：公司子公司江苏神华药业有限公司在经营的品种含复方灭活白葡萄球菌片 （用于慢性气管炎、支气管炎和支气管哮喘）、白葡萄球菌片（用于慢性支气管炎等呼吸道疾患引起的 咳嗽，痰多）。 3、2025年4月30日投资者关系活动记录表：公司积极布局银发大健康领域，主要通过以下两个方向进行 落实：一方面，公司积极开展慢病培训和服务，以药店为服务窗口，为老年人提供专业的健康咨询和用 药指导，提升慢病管理服务的深度和广度。另一方面，打造以老年人常见病为主的"福曼医"系列心脑血 管、降压、降糖类产品，并重点开发针对老年人健康养生需求的"国津"系列中药养生产品，满足老年人 群的健康管理需求。公司在银发大健康领域持续深耕，致力于为老年人提供更全面的健康服务和更优质 ...

Investment Rating - The investment rating for the pharmaceutical industry is "Positive" (maintained) [4] Core Insights - The report emphasizes the potential of brain-computer interface (BCI) technology and AI medical applications, predicting significant developments in 2026. It suggests focusing on innovative drug stocks and medical technology themes, particularly in the context of an aging population and the recovery of consumer spending in healthcare [3][5][42]. Summary by Sections 1. Policy Catalysts and BCI Application Potential - The brain-computer interface (BCI) technology is highlighted as a key area of growth, with the market expected to reach approximately $2.62 billion by 2024 and grow to $12.4 billion by 2034, reflecting a compound annual growth rate (CAGR) of 17.4% from 2025 to 2034 [12][18]. - The medical sector is projected to account for about 46% of the BCI application market in 2024, focusing on areas such as neurological rehabilitation and sensory diagnostics [13][18]. 2. Industry Perspective: Innovation and Global Expansion - The pharmaceutical index has shown a decline of 0.18% from December 22 to December 26, 2025, with a year-to-date increase of 14.29%. The report notes a significant number of stocks experiencing both gains and losses during this period [25][30]. - The report identifies key stocks to watch, including innovative drug companies and those involved in the BCI and AI medical sectors, suggesting a focus on companies like Heng Rui Medicine, Zai Lab, and others [42][45]. 3. Investment Opportunities - The report suggests that the pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs leading the way. It highlights the increasing global competitiveness of Chinese pharmaceutical companies and their growing capabilities in international markets [41][42]. - Specific recommendations include focusing on innovative drugs, medical devices, and companies involved in the BCI sector, with a particular emphasis on those with strong fundamentals and potential for recovery in 2026 [42][44].

截至9月30日，苑东生物股东户数6482.00，较上期增加18.67%；人均流通股27234股，较上期减少 15.74%。2025年1月-9月，苑东生物实现营业收入10.19亿元，同比减少2.00%；归母净利润2.20亿元，同 比增长1.45%。 分红方面，苑东生物A股上市后累计派现3.41亿元。近三年，累计派现2.12亿元。 12月29日，苑东生物盘中下跌2.09%，截至11:18，报58.70元/股，成交7644.89万元，换手率0.73%，总 市值103.62亿元。 资金流向方面，主力资金净流出276.58万元，特大单买入895.77万元，占比11.72%，卖出713.87万元， 占比9.34%；大单买入654.26万元，占比8.56%，卖出1112.73万元，占比14.56%。 苑东生物今年以来股价涨97.60%，近5个交易日涨0.24%，近20日涨9.66%，近60日涨7.02%。 资料显示，成都苑东生物制药股份有限公司位于四川省成都市双流区安康路8号，成立日期2009年6月1 日，上市日期2020年9月2日，公司主营业务涉及化学原料药和化学药制剂的研发、生产与销售。主营业 务收入构成为：制剂销售7 ...

Core Viewpoint - TaiLong Pharmaceutical experienced a stock price decline of 2.06% on December 29, with a current price of 6.65 CNY per share and a market capitalization of 3.816 billion CNY [1] Group 1: Financial Performance - For the period from January to September 2025, TaiLong Pharmaceutical reported a revenue of 1.187 billion CNY, representing a year-on-year decrease of 11.47% [2] - The net profit attributable to the parent company for the same period was 25.3255 million CNY, down 12.36% year-on-year [2] - The company has distributed a total of 112 million CNY in dividends since its A-share listing, with 15.5307 million CNY distributed over the last three years [3] Group 2: Stock Market Activity - The stock price of TaiLong Pharmaceutical has increased by 30.65% year-to-date, but has seen a decline of 5.41% over the last five trading days and 9.77% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" three times this year, with the most recent appearance on December 10, where it recorded a net buy of -8.4516 million CNY [1] - As of September 30, 2025, the number of shareholders decreased to 40,400, while the average circulating shares per person increased by 1.09% to 14,190 shares [2] Group 3: Business Overview - TaiLong Pharmaceutical, established on August 31, 1998, operates in the pharmaceutical manufacturing sector, focusing on traditional Chinese medicine, chemical drug manufacturing, and pharmaceutical wholesale [2] - The company's revenue composition includes 70.59% from drug manufacturing, 14.71% from drug research services, and 14.42% from drug material circulation [2] - The company is categorized under the pharmaceutical and biological industry, specifically in traditional Chinese medicine [2]

本周，市场继续反弹。从12月17日开始，上证指数日K线八连涨，追平了今年4月8日-17日的八连 涨纪录。 当前已是牛市，且慢牛特征明显，看多做多是主旋律，仅需要在不同的行情阶段适当控制一下节奏 及注意策略即可。 从全周的表现来看，市场呈现"中间更强"的特征，中证500指数、创业板指数周涨幅位居前两位， 涨幅均超过3.9%；微盘股指数涨幅最小，全周仅涨0.7%。 那么，八连涨之后，市场会再创新高吗？后市机会在哪里？今天，达哥和牛博士就大家关心的话题 进行讨论。 牛博士：达哥，你好，又到周末我们聊行情的时间。虽然本周大盘涨幅很小，但大盘五连阳以及热 点发力确实让市场暖意明显。对于后市，你是如何看待的？ 道达：对于大市及市场风格，除了宽基指数之外，我平时也观察一些风格指数。 就在本周，平均股价指数创下了本轮牛市以来的新高，这是市场对后续行情看好的表现。 此外，主要指数中，上证指数、深证成指、创业板指数距离年内高点还有不到2%的差距。 就上证指数来看，目前距离9-10月的上升趋势线已经非常近了，下周一很有可能突破这条趋势线。 12月8日，上证指数反弹到该趋势线附近时遇阻，并展开调整。另外，达哥本周也提过，年内上证 指 ...

12月29日，百利天恒盘中下跌2.04%，截至09:49，报331.66元/股，成交4767.21万元，换手率0.14%，总 市值1369.34亿元。 百利天恒所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：抗癌治癌、创新药、抗 癌药物、生物医药、中药等。 截至9月30日，百利天恒股东户数5979.00，较上期增加25.08%；人均流通股17208股，较上期减少 20.05%。2025年1月-9月，百利天恒实现营业收入20.66亿元，同比减少63.52%；归母净利润-4.95亿元， 同比减少112.16%。 机构持仓方面，截止2025年9月30日，百利天恒十大流通股东中，中欧医疗健康混合A（003095）位居 第三大流通股东，持股370.19万股，相比上期减少57.78万股。香港中央结算有限公司位居第四大流通股 东，持股289.57万股，相比上期减少69.64万股。华夏上证科创板50成份ETF（588000）位居第五大流通 股东，持股283.37万股，相比上期减少159.13万股。易方达上证科创板50ETF（588080）位居第六大流 通股东，持股229.92万股，相比上期减少101.89万股 ...

创新药行业：跨越拐点，迎接价值兑现新纪元 20251227 摘要 Q&A 2025 年创新药市场的整体表现如何？ 2025 年创新药市场的表现贯穿了前三个季度，主要以 BD（商业开发）为线索 不断演绎。H 股在这一领域领先于 A 股。年初，恒生科技带动港股流动性复苏， 港股创新药同步迎来估值修复，但未取得超额收益。4 月份，由于关税和贸易 战争端的到来，创新药作为 IP 交易不涉及实体交易关税，被视为类避险资产， 从而走出一定超额收益。5 月份，三生制药与辉瑞就 PD-1 和 VEGF 双抗达成 大额 BD 交易，引发第一波加速行情。7 月后，市场对 BD 预期增强，引发第二 波行情加速。但随后进入盘整期，截至年底，相对于指数来说，创新药仍取得 显著超额收益。 为什么 12 月 15 日创新药板块出现显著下跌？ 2024 年创新药板块经历估值修复，虽受贸易摩擦和一品红事件影响出 现波动，但全年仍取得超额收益，市场对 BD 交易预期增强是重要驱动 因素。 当前深度调整有助于挤出创新药估值泡沫，促使资金集中于真正具备全 球创新实力和清晰商业化路径的公司，为产业长远发展蓄力。 多项政策落地支持创新药行业发展，包括全 ...